The first chance for Americans to see how strong the evidence really is about the Pfizer and BioNTech coronavirus vaccine will come in early December at a public meeting of the US Food and Drug Administration scientific advisers. So far, what is known is based only on statements from Pfizer and BioNTech. They will recommend not just whether FDA should allow broader use of the vaccine generally but if so, for whom. For example, is there enough proof the vaccine works as well for older, sicker adults as for younger, healthier people? “We don’t know what that vote’s going to be,” said former FDA vaccine chief Norman Baylor.-AP

Source: The Standard November 20, 2020 14:15 UTC